Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 12/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483185 | 0.89 | HDAC3 (0.48) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL1483637 | 0.75 | HDAC1 (0.50) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL6450357 | 0.74 | NAMPT (0.46) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL3683038 | 0.73 | MAPT (0.53) | NPC1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL12545781 | 0.72 | ALDH1A1 (0.48) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL1483582 | 0.72 | HDAC1 (0.49) | HDAC1NPC1ALDH1A1TP53RAB9A | |
| SCHEMBL30736094 | 0.72 | GRM5 (0.50) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL1483919 | 0.71 | AR (0.53) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL11744810 | 0.67 | MEN1 (0.60) | NPC1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL4586297 | 0.67 | MAOB (0.45) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314103-B2 | Pyridyl derivatives, their preparation and use | Piramal Enterprises Limited (IN) | 2012-11-20 | — | — | US | claimed |
| US-20110077252-A1 | PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE | Piramal Enterprises Limited (IN) | 2011-03-31 | — | — | US | claimed |
| US-8314103-B2 | Pyridyl derivatives, their preparation and use | Piramal Enterprises Limited (IN) | 2012-11-20 | — | — | US | disclosed |
| US-20110077252-A1 | PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE | Piramal Enterprises Limited (IN) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077252-A1 | PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE | HIF1AN, HIF1A, MTOR | HDAC3 904/4885HDAC1 761/4885HDAC8 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.